Who are LAMA/LABA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aclidinium bromide/formoterol fumarate combination, TIO/OLO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lama-laba.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

LAMA/LABA — Competitive Intelligence Brief

LAMA/LABA (LAMA/LABA) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LAMA/LABA combination bronchodilator. Area: Respiratory/Pulmonology.

phase 3 LAMA/LABA combination bronchodilator Muscarinic M3 receptor and beta-2 adrenergic receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

LAMA/LABA (LAMA/LABA) — Queen's University. LAMA/LABA is a dual bronchodilator combining a long-acting muscarinic antagonist and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LAMA/LABA TARGET	LAMA/LABA	Queen's University	phase 3	LAMA/LABA combination bronchodilator	Muscarinic M3 receptor and beta-2 adrenergic receptor
Aclidinium bromide/formoterol fumarate combination	Aclidinium bromide/formoterol fumarate combination	AstraZeneca	marketed	Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor and beta-2 adrenergic receptor
TIO/OLO	TIO/OLO	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor and beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LAMA/LABA combination bronchodilator class)

Queen's University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LAMA/LABA — Competitive Intelligence Brief. https://druglandscape.com/ci/lama-laba. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab